According to incomplete statistics from Innovation Radar, from June 30 to July 6, the global biopharmaceutical fieldA total of 24 transaction events were disclosed, with a potential total transaction value of nearly 5 billion US dollars.。

The largest M&A deal in terms of amount last week was eye-catching.AbbVie Announces $2.1 Billion Acquisition of Capstan Therapeutics, including the targeted lipid nanoparticle (tLNP) technology platform and core asset CAR-T therapy CPTX2309,Strengthen the layout in the field of immune diseases.CPTX2309Delivering mRNA payloads encoding CD19-targeted chimeric antigen receptors into CD8-expressing T cells effectively generates CAR-T cell therapy directly in vivo. This approach can eliminate pathogenic B cells, potentially resetting the immune system and offering a therapeutic option for B cell-mediated autoimmune diseases.

Collaborative R&D was another major highlight last week.Unnatural Products and Argenx Announce Collaboration Worth Over $1.5 Billion, will leverage an AI platform to discover and develop oral macrocyclic peptide drugs for "undruggable" disease targets. Also focusing on AI,XtalPi Deepens Strategic Cooperation with Pfizer, jointly build a molecular simulation platform to accelerate the discovery and development process of small molecule drugs.

In the field of anti-infectives,Swiss Biopharmaceutical Company BioVersys Collaborates with Shionogi in a Deal Worth up to 484 Million Swiss Francs, jointly developing the innovative antibiotic BV500 project for the treatment of drug-resistant non-tuberculous mycobacteria (NTM) infections. Derived from BioVersys' proprietary ansamycin chemistry platform, BV500 has the potential to become a first-line treatment for NTM infections.

In the field of cancer,Hancock Biotech Subsidiary FBD Biologics Licenses SIRPα-Fc Fusion Protein HCB101 to Henlius for a Potential Total of $202 MillionIt is reported that HCB101 can bind to CD47 with high affinity, inhibit the binding of wild-type human signal regulatory protein α (SIRPα), and enhance the phagocytosis of tumor cells by macrophages.

Readers, please star ⭐Chuangjianhui to receive updates第一时间收到推送.

Disclaimer: This article is for the purpose of information exchange only. The views expressed in the article do not represent the position of WuXi AppTec, nor does WuXi AppTec support or oppose the views mentioned in the article. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: Welcome to share to Moments for personal use. Unauthorized media or institutions are prohibited from reprinting or copying in any form to other platforms. For reprint authorization, please contact"Innovation Insight"Contact us by leaving a message on our WeChat Official Account.

More Data Content Recommended

Click "InSee", Sharing Chuangjianhui Health New Trends